# Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study

> **NCT01418937** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 164 (actual)

## Conditions studied

- Infections, Papillomavirus

## Interventions

- **BIOLOGICAL:** CervarixTM (GSK580299)

## Key facts

- **NCT ID:** NCT01418937
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-29
- **Primary completion:** 2015-01-09
- **Final completion:** 2015-01-09
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2018-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01418937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01418937, "Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01418937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*